Das Produkt wurde korrekt in den Warenkorb gelegt.

discount label
H-KLVALGINAV-OH
3D-Ansicht

Biosynth logo

H-KLVALGINAV-OH

Ref. 3D-PP45226

1mg
232,00 €
10mg
273,00 €
100mg
497,00 €
Voraussichtliche Lieferung in Vereinigte Staaten, am Freitag 27. Dezember 2024

Produktinformation

Name:
H-KLVALGINAV-OH
Synonyme:
  • NH2-Lys-Leu-Val-Ala-Leu-Gly-Ile-Asn-Ala-Val-OH
Beschreibung:

Peptide H-KLVALGINAV-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-KLVALGINAV-OH include the following: How an alloreactive T-cell receptor achieves peptide and MHC specificity Y Wang , NK Singh , TT Spear - Proceedings of the , 2017 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.1700459114 Clonal deletion prunes but does not eliminate self-specific alphabeta CD8+ T lymphocytes W Yu, N Jiang , PJR Ebert, BA Kidd , S Muller, PJ Lund - Immunity, 2015 - cell.comhttps://www.cell.com/immunity/pdf/S1074-7613(15)00181-8.pdf Inefficient recognition of autologous viral sequences by intrahepatic hepatitis C virus-specific cytotoxic T lymphocytes in chronically infected subjects VM Giuggio, HL Bonkovsky, J Smith, AL Rothman - Virology, 1998 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0042682298994016 Characterization of intrahepatic T-lymphocytes in patients with chronic hepatitis C virus infection: a dissertation VM Giuggio - 2000 - repository.escholarship.umassmed https://repository.escholarship.umassmed.edu/handle/20.500.14038/31507 Liver Organoid and T Cell Coculture Models Cytotoxic T Cell Responses against Hepatitis C Virus V Natarajan , CR Simoneau, AL Erickson, NL Meyers - Biorxiv, 2021 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/2021.08.10.455738.abstract Modelling T-cell immunity against hepatitis C virus with liver organoids in a microfluidic coculture system V Natarajan , CR Simoneau , AL Erickson - Open , 2022 - royalsocietypublishing.orghttps://royalsocietypublishing.org/doi/abs/10.1098/rsob.210320 Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability TT Spear, TP Riley, GE Lyons - Journal of Leucocyte , 2016 - academic.oup.comhttps://academic.oup.com/jleukbio/article-abstract/100/3/545/6932858 Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity RH McMahan , L Golden-Mason - The Journal of , 2010 - Am Soc Clin Investighttps://www.jci.org/articles/view/43127 Determinants of viral clearance and persistence during acute hepatitis C virus infection R Thimme, D Oldach, KM Chang , C Steiger - The Journal of , 2001 - rupress.orghttps://rupress.org/jem/article-abstract/194/10/1395/39380 Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire M Wölfl, A Rutebemberwa, T Mosbruger - The Journal of , 2008 - journals.aai.orghttps://journals.aai.org/jimmunol/article/181/9/6435/78899 IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses JW Han , PS Sung , SH Hong , H Lee , JY Koh , H Lee - Journal of , 2020 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0168827820301070 Cutting edge: identification of hepatitis C virus-specific CD8+ T cells restricted by donor HLA alleles following liver transplantation HR Rosen, DJ Hinrichs, RL Leistikow - The Journal of , 2004 - journals.aai.orghttps://journals.aai.org/jimmunol/article/173/9/5355/36231 Transplantation immunology: what the clinician needs to know for immunotherapy HR Rosen - Gastroenterology, 2008 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0016508508003004 Targeting naturally occurring epitope variants of hepatitis C virus with high-affinity T-cell receptors H Zhang, J Zhang, L Chen, Z Weng - Journal of General , 2017 - microbiologyresearch.orghttps://www.microbiologyresearch.org/content/journal/jgv/10.1099/jgv.0.000656 Genetic variability of hepatitis C virus non-structural protein 3 and virus-specific CD8+ response in patients with chronic hepatitis C FX Lopez-Labrador, XS He - Journal of medical , 2004 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.20036 Hepatitis C virus-specific cellular and humoral immune responses following immunization with a multi-epitope fusion protein F Qiu, S Bi, Y Wang, M Guo, Y Yi - International , 2012 - spandidos-publications.comhttps://www.spandidos-publications.com/ijmm/29/1/12 Identification of naturally processed hepatitis C virus-derived major histocompatibility complex class I ligands B Wölk, C Trautwein, B Buchele, N Kersting, HE Blum - PloS one, 2012 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0029286&imageURI=info:doi/10.1371/journal.pone.0029286.g003 The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1 AY Kim, GM Lauer , K Ouchi , MM Addo , M Lucas - Blood, 2005 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/105/3/1170/19641 Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall AK Thomas-Kaskel, R Zeiser , R Jochim - Journal of Cancer, 2006 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.22097 RACER-m leverages structural features for sparse T Cell specificity prediction A Wang , X Lin , KN Chau , JN Onuchic , H Levine - Science , 2024 - science.orghttps://www.science.org/doi/abs/10.1126/sciadv.adl0161 Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of A Sistigu, L Bracci , M Valentini, E Proietti, R Bona - Vaccine, 2011 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X11002945

Hinweis:
Unsere Produkte sind nur für Laborzwecke. Für jede andere Verwendung, bitte melden sie sich bei uns.
Marke:
Biosynth
Langzeitlagerung:
Hinweise:

Chemische Eigenschaften

MDL:
Schmelzpunkt:
Siedepunkt:
Flammpunkt:
Dichte:
Konzentration:
EINECS:
Merck:
HS-Code:

Gefahrenhinweise

UN-Nummer:
EQ:
Klasse:
H-Sätze:
P-Sätze:
Flugverbot:
Gefahrenhinweis:
Verpackungsgruppe:
LQ:

Technische Anfrage zu: 3D-PP45226 H-KLVALGINAV-OH

Bitte verwenden Sie stattdessen den Warenkorb, um ein Angebot oder eine Bestellung anzufordern

Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.

* Obligatorische felder
Willkommen bei CymitQuimica!Wir verwenden Cookies, um Ihren Besuch zu verbessern. Wir schließen Werbung nicht ein.

Bitte beachten Sie unsere Cookie-Richtlinie  für weitere Details oder passen Sie Ihre Einstellungen unter “Konfigurieren” an.